← All trials
NCT05175625
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 15, 2021
- Primary completion
- Dec 30, 2021
- Completion date
- Jun 20, 2022
- First posted
- Jan 4, 2022
- Last posted
- Oct 14, 2022
- Enrollment
- 300
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- CinnagenLead sponsor
- Vaxine Pty LtdCollaborator
- Shahid Beheshti University of Medical SciencesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.